专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11607412B2 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) 有权
$Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)$
公开(公告)号：US11607412B2
公开(公告)日：2023-03-21
申请号：US17410897
申请日：2021-08-24
申请人： Tenax Therapeutics, Inc.
发明人： Stuart Rich , Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K31/495 , A61K47/12 , A61K47/02 , A61K47/10 , A61K9/00 , A61K47/26 , A61K47/40 , A61K45/06 , A61K31/7048 , A61K31/55 , A61K31/502 , A61K38/22 , A61P9/12 , A61P9/04 , A61K31/41 , A61K31/216 , A61K47/32
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

2. 发明申请

US20210393625A1 LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) 有权
公开(公告)号：US20210393625A1
公开(公告)日：2021-12-23
申请号：US17410897
申请日：2021-08-24
申请人： Tenax Therapeutics, Inc.
发明人： Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K31/495 , A61K47/12 , A61K47/02 , A61K47/10 , A61K9/00 , A61K47/26 , A61K47/40 , A61K45/06 , A61K31/7048 , A61K31/55 , A61K31/502 , A61K38/22 , A61P9/12 , A61P9/04 , A61K31/41 , A61K31/216 , A61K47/32
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

3. 发明授权

US11701355B2 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) 有权
$Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)$
公开(公告)号：US11701355B2
公开(公告)日：2023-07-18
申请号：US18057116
申请日：2022-11-18
申请人： Tenax Therapeutics, Inc.
发明人： Stuart Rich , Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K31/495 , A61K47/12 , A61K47/02 , A61K47/10 , A61K9/00 , A61K47/26 , A61K47/40 , A61K45/06 , A61K31/7048 , A61K31/55 , A61K31/502 , A61K38/22 , A61P9/12 , A61P9/04 , A61K31/41 , A61K31/216 , A61K47/32
CPC分类号： A61K31/50 , A61K9/0019 , A61K9/0053 , A61K31/216 , A61K31/41 , A61K31/495 , A61K31/502 , A61K31/55 , A61K31/7048 , A61K38/2221 , A61K38/2242 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/40 , A61P9/04 , A61P9/12
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

4. 发明申请

US20150374689A1 Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass 审中-公开
标题翻译：使用左西孟旦治疗需要心肺旁路的心脏手术患者的左心室收缩功能障碍
公开(公告)号：US20150374689A1
公开(公告)日：2015-12-31
申请号：US14751476
申请日：2015-06-26
申请人： TENAX Therapeutics, Inc.
发明人： John Kelley , Doug Randall , Douglas Hay
IPC分类号： A61K31/50
CPC分类号： A61K31/50
摘要： Methods of (i) reducing morbidity and/or mortality in a human patient undergoing cardiac surgery; (ii) preventing, or reducing the risk of development of, LCOS in a human patient undergoing cardiac surgery; or (iii) reducing the risk of, intensity of, or occurrence of, one or more postoperative adverse events in a human patient undergoing cardiac surgery. The methods can involve (a) a first period of administering to the patient levosimendan for about 1 hour, in which the administration of levosimendan during the first period is initiated: (i) before skin incision for the cardiac surgery, and (ii) at an infusion dose of about 0.2 μg/kg/min; and (b) a second period of administering to the patient levosimendan for about 23 hours, in which the administration of levosimendan during the second period is initiated at an infusion dose of about 0.1 μg/kg/min.
摘要翻译：（i）减少接受心脏手术的人类患者的发病率和/或死亡率的方法; （ii）在接受心脏手术的人类患者中预防或降低LCOS发展的风险; 或（iii）减少在接受心脏手术的人类患者中的一个或多个术后不良事件的风险，强度或发生的风险。所述方法可以包括（a）给患者左西孟旦施用约1小时的第一时期，其中在第一时期开始给予左西孟旦;（i）在皮肤切开心脏手术之前，和（ii）约0.2μg/ kg / min的输注剂量; 和（b）向患者左西孟旦施用约23小时的第二个时期，其中在约0.1μg/ kg / min的输注剂量下开始第二次给予左西孟旦。

5. 发明授权

US11213524B2 Pharmaceutical compositions for subcutaneous administration of levosimendan 有权
公开(公告)号：US11213524B2
公开(公告)日：2022-01-04
申请号：US16544098
申请日：2019-08-19
申请人： Tenax Therapeutics, Inc.
发明人： Doug Randall , Douglas Hay , Nancy J. M. Hecox
IPC分类号： A61K31/50 , A61K47/40 , A61K9/00 , A61K9/19
摘要： A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

6. 发明申请

US20210177840A1 LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) 有权
公开(公告)号：US20210177840A1
公开(公告)日：2021-06-17
申请号：US17122921
申请日：2020-12-15
申请人： Tenax Therapeutics, Inc.
发明人： Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K47/32 , A61K47/12 , A61K47/02 , A61K47/10 , A61K9/00 , A61K47/26 , A61K47/40 , A61K45/06 , A61K31/7048 , A61K31/55 , A61K31/502 , A61K38/22 , A61P9/12 , A61P9/04 , A61K31/41 , A61K31/216 , A61K31/495
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

7. 发明申请

US20200330463A1 Pharmaceutical Compositions for Subcutaneous Administration of Levosimendan 审中-公开
公开(公告)号：US20200330463A1
公开(公告)日：2020-10-22
申请号：US16544098
申请日：2019-08-19
申请人： Tenax Therapeutics, Inc.
发明人： Doug Randall , Douglas Hay , Nancy J.M. Hecox
IPC分类号： A61K31/50 , A61K47/40
摘要： A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

8. 发明公开

US20240269134A1 LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) 审中-公开
公开(公告)号：US20240269134A1
公开(公告)日：2024-08-15
申请号：US18621976
申请日：2024-03-29
申请人： Tenax Therapeutics, Inc.
发明人： Stuart Rich , Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K9/00 , A61K31/216 , A61K31/41 , A61K31/495 , A61K31/502 , A61K31/55 , A61K31/7048 , A61K38/22 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/40 , A61P9/04 , A61P9/12
CPC分类号： A61K31/50 , A61K9/0019 , A61K9/0053 , A61K31/216 , A61K31/41 , A61K31/495 , A61K31/502 , A61K31/55 , A61K31/7048 , A61K38/2221 , A61K38/2242 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/40 , A61P9/04 , A61P9/12
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

9. 发明授权

US11969424B2 Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) 有权
$Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)$
公开(公告)号：US11969424B2
公开(公告)日：2024-04-30
申请号：US17122921
申请日：2020-12-15
申请人： Tenax Therapeutics, Inc.
发明人： Stuart Rich , Douglas Randall , Douglas Hay
IPC分类号： A61K31/50 , A61K9/00 , A61K31/216 , A61K31/41 , A61K31/495 , A61K31/502 , A61K31/55 , A61K31/7048 , A61K38/22 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/40 , A61P9/04 , A61P9/12
CPC分类号： A61K31/50 , A61K9/0019 , A61K9/0053 , A61K31/216 , A61K31/41 , A61K31/495 , A61K31/502 , A61K31/55 , A61K31/7048 , A61K38/2221 , A61K38/2242 , A61K45/06 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/32 , A61K47/40 , A61P9/04 , A61P9/12
摘要： This invention relates to the treatment of Pulmonary Hypertension with heart failure with preserved ejection fraction (PH-HFpEF). More specifically, embodiments of the invention provide compositions and methods useful for the treatment of PH-HFpEF employing the use of levosimendan.

10. 发明申请

US20220096470A1 PHARMACEUTICAL COMPOSITIONS FOR SUBCUTANEOUS ADMINISTRATION OF LEVOSIMENDAN 有权
公开(公告)号：US20220096470A1
公开(公告)日：2022-03-31
申请号：US17545386
申请日：2021-12-08
申请人： Tenax Therapeutics, Inc.
发明人： Doug Randall , Douglas Hay , Nancy J. M. Hecox
IPC分类号： A61K31/50 , A61K47/40
摘要： A composition containing levosimendan, one or more solubilizing and/or stabilizing agents, and one or more additional pharmaceutically acceptable additives. The one or more solubilizing and/or stabilizing agents may be a cyclodextrin or a cyclodextrin derivative. The cyclodextrin derivative may be a derivative of an alpha-cyclodextrin, or beta-cyclodextrin, or a gamma-cyclodextrin. The cyclodextrin derivative may contain a butyl ether spacer group, an alkyl ether space group, or both. The one or more additional pharmaceutically acceptable additives may be a non-citrate buffer. The composition may be used in a method of treating a health condition, such as heart failure, pulmonary hypertension, chronic kidney disease, amyotrophic lateral sclerosis, stroke, in advance of a planned cardiac surgery, or other health conditions for which a minimally invasive or repeated administration of levosimendan may be beneficial. The composition may be administered subcutaneously.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式